Deep brain stimulator complications: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
[[File:Deep brain.jpg|thumb]] | [[File:Deep brain.jpg|thumb]] | ||
*FDA-approved for medication-refractory movement disorders (e.g. [[Parkinson's disease]], dystonia, essential tremor) and OCD | *FDA-approved for medication-refractory movement disorders (e.g. [[Parkinson's disease]], dystonia, essential tremor) and OCD | ||
**Being studied for use in [[epilepsy]], chronic pain, depression, PTSD | **Being studied for use in [[epilepsy]], chronic pain, [[depression]], PTSD | ||
*Single lead systems implanted into the thalamus | *Single lead systems implanted into the thalamus | ||
*Complication rates range from 7-65%<ref>Tabbal SD, Revilla FJ, Mink JW, et al. Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease. Neurosurgery. 2007;61(3 Suppl):119-27.</ref> | *Complication rates range from 7-65%<ref>Tabbal SD, Revilla FJ, Mink JW, et al. Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease. Neurosurgery. 2007;61(3 Suppl):119-27.</ref> | ||
==Clinical Features/Complication Types== | ==Clinical Features/Complication Types== | ||
*Infection | *[[Infection]] | ||
**Usually early after placement | **Usually early after placement | ||
**Infection rates ~3-10%<ref>Tabbal SD, Revilla FJ, Mink JW, et al. Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease. Neurosurgery. 2007;61(3 Suppl):119-27.</ref> | **Infection rates ~3-10%<ref>Tabbal SD, Revilla FJ, Mink JW, et al. Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease. Neurosurgery. 2007;61(3 Suppl):119-27.</ref> | ||
*Cerebral hemorrhage | *[[ICH|Cerebral hemorrhage]] | ||
*Lead fracture or migration | *Lead fracture or migration | ||
*Failure of device to improve tremor/motor symptoms | *Failure of device to improve tremor/motor symptoms | ||
*Paresthesias (temporary or permanent) | *[[Paresthesias]] (temporary or permanent) | ||
*Dysarthria, decreased verbal fluency | *[[Dysarthria]], decreased verbal fluency | ||
*Disequilibrium | *Disequilibrium | ||
*Affective changes (depression, apathy), impaired executive function, impulsivity | *Affective changes ([[depression]], apathy), impaired executive function, impulsivity | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Revision as of 20:39, 1 October 2019
Background
- FDA-approved for medication-refractory movement disorders (e.g. Parkinson's disease, dystonia, essential tremor) and OCD
- Being studied for use in epilepsy, chronic pain, depression, PTSD
- Single lead systems implanted into the thalamus
- Complication rates range from 7-65%[1]
Clinical Features/Complication Types
- Infection
- Usually early after placement
- Infection rates ~3-10%[2]
- Cerebral hemorrhage
- Lead fracture or migration
- Failure of device to improve tremor/motor symptoms
- Paresthesias (temporary or permanent)
- Dysarthria, decreased verbal fluency
- Disequilibrium
- Affective changes (depression, apathy), impaired executive function, impulsivity
Differential Diagnosis
Evaluation
- May need to observe with device in "off" position to distinguish between device malfunction and other acute neurologic deficit
Management
- Consult neurosurgery
Disposition
See Also
External Links
References
- ↑ Tabbal SD, Revilla FJ, Mink JW, et al. Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease. Neurosurgery. 2007;61(3 Suppl):119-27.
- ↑ Tabbal SD, Revilla FJ, Mink JW, et al. Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease. Neurosurgery. 2007;61(3 Suppl):119-27.